INDIANAPOLIS (April 12, 2021) --   In 2020, Indiana’s life sciences companies accessed over $9 billion in capital to grow and support innovation. The funding comes from a variety of sources including Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards, venture capital, initial public offerings and related public offerings, and mergers and acquisitions. BioCrossroads today issued their annual report, Indiana Life Sciences Capital 2020, which provides details on the funding events throughout the year. The $9 billion includes: $12.6 million SBIR awarded to 21 companies. $262 million in venture capital invested in 44 companies. $141.8 million accessed through public markets by three companies. $8.6 billion+ spent to acquire innovation, representing nine transactions. The market capitalization for Indiana’s public life sciences companies as of Dec. 31, 2020 was $297.6 billion and includes Eli Lilly and Company, Anthem, Zimmer [...]